Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone

International Journal of Cardiology

Volumn 227, Issue , 2017, Pages 462-466

  Lam, Phillip H ^a   Dooley, Daniel J ^a   Inampudi, Chakradhari ^b   Arundel, Cherinne ^c,d   Fonarow, Gregg C ^e   Butler, Javed ^f   Wu, Wen Chih ^g,h   Blackman, Marc R ^a,c,d   Anker, Markus S ⁱ   Deedwania, Prakash ^j   White, Michel ^k   Prabhu, Sumanth D ^l   Morgan, Charity J ^l   Love, Thomas E ^m   Aronow, Wilbert S ⁿ   Allman, Richard M ^o   Ahmed, Ali ^c,d  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f STONY BROOK UNIVERSITY   (United States)

^g PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h BROWN UNIVERSITY   (United States)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITÉ DE MONTRÉAL   (Canada)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^m CASE WESTERN RESERVE UNIVERSITY   (United States)

ⁿ NEW YORK MEDICAL COLLEGE   (United States)

^o DEPARTMENT OF VETERANS AFFAIRS   (United States)

more..

Author keywords

30 day all cause readmission; Heart failure; Medicare beneficiaries; Spironolactone

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

AFRICAN AMERICAN; AGED; ALL CAUSE MORTALITY; ALL CAUSE READMISSION; ARTICLE; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; FEMALE; HEART FAILURE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL PATIENT; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; MEDICARE; MORTALITY; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PRESCRIPTION; PRIORITY JOURNAL; PROPENSITY SCORE; ALABAMA; HEART STROKE VOLUME; INSURANCE; PATHOPHYSIOLOGY; RISK FACTOR; TREATMENT OUTCOME; UNITED STATES;

ALABAMA; FEMALE; HEART FAILURE; HUMANS; INSURANCE BENEFITS; MALE; MEDICARE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PATIENT READMISSION; RISK FACTORS; SPIRONOLACTONE; STROKE VOLUME; TREATMENT OUTCOME; UNITED STATES;

EID: 85005965459     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.11.006     Document Type: Article

References (39)

1. [1] Jencks, S.F., Williams, M.V., Coleman, E.A., Rehospitalizations among patients in the Medicare fee-for-service program. N. Engl. J. Med. 360 (2009), 1418–1428.
2. [2] Rau, J., Hospitals face pressure to avert readmissions. N. Y. Times, November 16, 2012 ( http://www.nytimes.com/2012/11/27/health/hospitals-face-pressure-from-medicare-to-avert-readmissions.html. Accessed July 10, 2016).
3. [3] Ponikowski, P., Anker, S.D., AlHabib, K.F., et al. Heart failure: preventing disease and death worldwide. ESC Heart Fail. 1 (2014), 4–25.
4. [4] Feltner, C., Jones, C.D., Cene, C.W., et al. Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta-analysis. Ann. Intern. Med. 160 (2014), 774–784.
5. [5] Ahmed, A., Bourge, R.C., Fonarow, G.C., et al. Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure. Am. J. Med. 127 (2014), 61–70.
6. [6] Bourge, R.C., Fleg, J.L., Fonarow, G.C., et al. Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am. J. Med. 126 (2013), 701–708.
7. [7] Sanam, K., Bhatia, V., Bajaj, N.S., et al. Renin-angiotensin system inhibition and lower 30-day all-cause readmission in Medicare beneficiaries with heart failure. Am. J. Med., 2016.
8. [8] Feller, M.A., Mujib, M., Zhang, Y., et al. Baseline characteristics, quality of care, and outcomes of younger and older Medicare beneficiaries hospitalized with heart failure: findings from the Alabama Heart Failure Project. Int. J. Cardiol. 162 (2012), 39–44.
9. [9] Ahmed, A., Fonarow, G.C., Zhang, Y., et al. Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease. Am. J. Med. 125 (2012), 399–410.
10. [10] Ahmed, A., Rich, M.W., Zile, M., et al. Renin-angiotensin inhibition in diastolic heart failure and chronic kidney disease. Am. J. Med. 126 (2013), 150–161.
11. [11] Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 62 (2013), e147–e239.
12. [12] Danaei G, Tavakkoli M, Hernan MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am. J. Epidemiol.;175:250–62.
13. [13] Rosenbaum, P.R., Rubin, D.B., The central role of propensity score in observational studies for causal effects. Biometrika 70 (1983), 41–55.
14. [14] Rubin, D.B., Using propensity score to help design observational studies: application to the tobacco litigation. Health Serv. Outcome Res. Methodol. 2 (2001), 169–188.
15. [15] Ahmed, M.I., Ekundayo, O.J., Mujib, M., et al. Mild hyperkalemia and outcomes in chronic heart failure: a propensity matched study. Int. J. Cardiol. 144 (2010), 383–388.
16. [16] Ritchie, C., Ekundayo, O.J., Muchimba, M., et al. Effects of diabetes mellitus in patients with heart failure and chronic kidney disease: a propensity-matched study of multimorbidity in chronic heart failure. Int. J. Cardiol. 134 (2009), 330–335.
17. [17] Ekundayo, O.J., Adamopoulos, C., Ahmed, M.I., et al. Oral potassium supplement use and outcomes in chronic heart failure: a propensity-matched study. Int. J. Cardiol. 141 (2010), 167–174.
18. [18] Ahmed, A., Husain, A., Love, T.E., et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur. Heart J. 27 (2006), 1431–1439.
19. [19] Adamopoulos, C., Meyer, P., Desai, R.V., et al. Absence of obesity paradox in patients with chronic heart failure and diabetes mellitus: a propensity-matched study. Eur. J. Heart Fail. 13 (2011), 200–206.
20. [20] Patel, K., Fonarow, G.C., Kitzman, D.W., et al. Angiotensin receptor blockers and outcomes in real-world older patients with heart failure and preserved ejection fraction: a propensity-matched inception cohort clinical effectiveness study. Eur. J. Heart Fail. 14 (2012), 1179–1188.
21. [21] Ahmed, M.I., White, M., Ekundayo, O.J., et al. A history of atrial fibrillation and outcomes in chronic advanced systolic heart failure: a propensity-matched study. Eur. Heart J. 30 (2009), 2029–2037.
22. [22] Wahle, C., Adamopoulos, C., Ekundayo, O.J., Mujib, M., Aronow, W.S., Ahmed, A., A propensity-matched study of outcomes of chronic heart failure (HF) in younger and older adults. Arch. Gerontol. Geriatr. 49 (2009), 165–171.
23. [23] Hernandez, A.F., Mi, X., Hammill, B.G., et al. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. JAMA 308 (2012), 2097–2107.
24. [24] Lund, L.H., Svennblad, B., Melhus, H., Hallberg, P., Dahlstrom, U., Edner, M., Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study. Circ. Heart Fail. 6 (2013), 174–183.
25. [25] Pitt, B., Zannad, F., Remme, W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341 (1999), 709–717.
26. [26] Zannad, F., McMurray, J.J., Krum, H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364 (2011), 11–21.
27. [27] Pitt, B., Remme, W., Zannad, F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348 (2003), 1309–1321.
28. [28] Cowie, M.R., Anker, S.D., Cleland, J.G.F., et al. Improving care for patients with acute heart failure: before, during and after hospitalization. ESC Heart Fail. 1 (2014), 110–145.
29. [29] Konstam, M.A., Heart failure in the lifetime of Musca domestica (the common housefly). JACC Heart Fail. 1 (2013), 178–180.
30. [30] Butler, J., Arbogast, P.G., Daugherty, J., Jain, M.K., Ray, W.A., Griffin, M.R., Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. J. Am. Coll. Cardiol. 43 (2004), 2036–2043.
31. [31] Curtis, L.H., Mi, X., Qualls, L.G., et al. Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. Am. Heart J. 165 (2013), 979–986, e1.
32. [32] Svensson, M., Gustafsson, F., Galatius, S., Hildebrandt, P.R., Atar, D., How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?. J. Card. Fail. 10 (2004), 297–303.
33. [33] Vardeny, O., Wu, D.H., Desai, A., et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J. Am. Coll. Cardiol. 60 (2012), 2082–2089.
34. [34] Inampudi, C., Parvataneni, S., Morgan, C.J., et al. Spironolactone use and higher hospital readmission for Medicare beneficiaries with heart failure, left ventricular ejection fraction < 45%, and estimated glomerular filtration rate < 45 ml/min/1.73 m(2.). Am. J. Cardiol. 114 (2014), 79–82.
35. [35] Schefold, J.C., Lainscak, M., Hodoscek, L.M., Blöchlinger, S., Doehner, W., S. vH. Single baseline serum creatinine measurements predict mortality in critically ill patients hospitalized for acute heart failure. ESC Heart Fail. 2 (2015), 122–128.
36. [36] Bhatia, V., Bajaj, N.S., Sanam, K., et al. Beta-blocker use and 30-day all-cause readmission in Medicare beneficiaries with systolic heart failure. Am. J. Med. 128 (2015), 715–721.
37. [37] Rosenbaum, P.R., Sensitivity to hidden bias. Rosenbaum, P.R., (eds.) Observational Studies, vol. 1, 2002, Springer-Verlag, NewYork, 105–170.
38. [38] Clarke, R., Shipley, M., Lewington, S., et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am. J. Epidemiol. 150 (1999), 341–353.
39. [39] Shewan, L.G., Coats, A.J., Ethics in the authorship and publishing of scientific articles. Int. J. Cardiol. 144 (2010), 1–2.